BK21 Program of Bio-Molecular Seminar

 

▶ subject : Structural Studies on EGF Receptors and anti-EGFR mAB Drugs

▶ Speaker : Hyun-Soo Cho (Dept. of System Biology, College of Life Science and Biotechnology, Yonsei University)

▶ Date : 4:00PM/ Aug. 16(Tues)/ 2011

▶ Place : (1F) Conference Room, Postech Biotech Center

 

*Abstract
The ErbB family of receptor tyrosine kinases in humans comprises the Epidermal Growth Factor Receptor (EGFR, ErbB1, HER1), ErbB2 (HER2, Neu), ErbB3 (HER3), and ErbB4 (HER4). These receptors consist of an extracellular ligand-binding region, a single transmembrane spanning region, and a cytoplasmic tyrosine kinase. Ligand binding to the extracellular regions of these receptors leads to receptor dimerization, activation of the tyrosine kinase, and initiation of an intracellular signaling cascade. Each of these receptors promotes cell growth and differentiation at multiple stages of embryonic development, and inappropriate activation of these receptors has been shown to contribute to the cause and severity of several human cancers. Inhibiting activated ErbB receptors has proven useful for treating human cancer, and two monoclonal antibodies against ErbBs, Erbitux and Herceptin, and three small-molecule kinase inhibitors, Tykerb, Tarceva and Iressa, have been approved for treatment of specific cancers. Structural studies have revealed the molecular details of ligand-induced dimerization and kinase activation as well as the mechanism of ErbB-targeted drugs.

☎ Inquiry : Sung Ho Ryu (279-2292)